tiprankstipranks
Elite Pharmaceuticals (ELTP)
OTHER OTC:ELTP
US Market

Elite Pharmaceuticals (ELTP) Stock Price & Analysis

110 Followers

ELTP Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.03 - $0.21
Previous Close$0.15
Volume170.93K
Average Volume (3M)1.45M
Market Cap
$154.50M
Enterprise Value$156.57M
Total Cash (Recent Filing)$5.82M
Total Debt (Recent Filing)$7.89M
Price to Earnings (P/E)10.3
Beta0.16
Jun 12, 2024
EPS EstimateN/A
Next Dividend Ex-DateN/A
Expense RatioN/A
Share Statistics
EPS (TTM)0.01
Shares Outstanding1,017,781,199
10 Day Avg. Volume578,430
30 Day Avg. Volume1,454,545
Standard Deviation0.21
R-Squared0.00149
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)3.86
Price to Sales (P/S)4.54
Price to Cash Flow (P/CF)-16.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.31
Enterprise Value/Gross Profit9.44
Enterprise Value/Ebitda404.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0

Financials

Annual

Ownership Overview

27.09%0.00%<0.01%72.90%
27.09% Insiders
<0.01% Other Institutional Investors
72.90% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

ELTP FAQ

What was Elite Pharmaceuticals’s price range in the past 12 months?
Elite Pharmaceuticals lowest stock price was $0.03 and its highest was $0.21 in the past 12 months.
    What is Elite Pharmaceuticals’s market cap?
    Currently, no data Available
    When is Elite Pharmaceuticals’s upcoming earnings report date?
    Elite Pharmaceuticals’s upcoming earnings report date is Jun 12, 2024 which is in 76 days.
      How were Elite Pharmaceuticals’s earnings last quarter?
      Elite Pharmaceuticals released its earnings results on Feb 14, 2024. The company reported $0.001 earnings per share for the quarter, beating the consensus estimate of N/A by $0.001.
        Is Elite Pharmaceuticals overvalued?
        According to Wall Street analysts Elite Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Elite Pharmaceuticals pay dividends?
          Elite Pharmaceuticals does not currently pay dividends.
          What is Elite Pharmaceuticals’s EPS estimate?
          Elite Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Elite Pharmaceuticals have?
          Elite Pharmaceuticals has 1,017,781,200 shares outstanding.
            What happened to Elite Pharmaceuticals’s price movement after its last earnings report?
            Elite Pharmaceuticals reported an EPS of $0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -10%.
              Which hedge fund is a major shareholder of Elite Pharmaceuticals?
              Among the largest hedge funds holding Elite Pharmaceuticals’s share is Fisher Asset Management LLC. It holds Elite Pharmaceuticals’s shares valued at 11K.
                ---

                Elite Pharmaceuticals Stock Smart Score

                Company Description

                Elite Pharmaceuticals

                Elite Pharmaceuticals, Inc. engages in the development and manufacture of pharmacological abuse-deterrent opioid products. It operates through the Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA) segments. The ANDA segment includes generic pharmaceuticals. The NDA segment comprises the branded pharmaceuticals. The company was founded on October 1, 1997 and is headquartered in Northvale, NJ.
                ---
                Similar Stocks
                Company
                Price & Change
                Follow
                Akari Therapeutics
                Acorda Therapeutics
                BioCryst
                Catalyst Pharma
                Popular Stocks
                ---
                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis